Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by Bunge on Feb 16, 2021 7:40am

L2

Level 2 Quote

Level two quotes - Bid
Number of Shares Bid Price
 
22,500 shares
22,500 0.290
 
1,000 shares
1,000 0.280
 
44,500 shares
44,500 0.275
 
7,500 shares
7,500 0.265
 
6,000 shares
6,000 0.260
 
13,500 shares
13,500 0.255
 
6,000 shares
6,000 0.250
 
22,000 shares
22,000 0.240
 
122,000 shares
122,000 0.235
 
97,500 shares
97,500 0.230
Level two quotes - Ask
Ask Price Number of Shares
0.290 48,500
 
48,500 shares
0.295 10,000
 
10,000 shares
0.300 232,500
 
232,500 shares
0.305 5,000
 
5,000 shares
0.310 51,500
 
51,500 shares
0.315 6,000
 
6,000 shares
0.320 34,000
 
34,000 shares
0.325 90,000
 
90,000 shares
0.330 120,000
 
120,000 shares
0.340 56,500  
Comment by ScienceFirst on Feb 16, 2021 8:18am
Level II 2 hours before the opening means absolutely nothing. Such an amateure this Bungee!
Comment by StevenBirch on Feb 16, 2021 8:59am
Thanks Bunge, showing a $0.30 opening now. Let's see if that can hold or if not at least close higher today. Positive Tuesday!
Comment by Sunvalley on Feb 16, 2021 9:03am
Thank you Bunge. I  appreciate you taking the time to inform the board.
Comment by StevenBirch on Feb 16, 2021 10:20am
Looks like these little fake selloffs should be bought. There is more than one seller but TD seems to initiate it most of the time and are is there to cross at the bottom - as well as anonymous.
Comment by ScienceFirst on Feb 16, 2021 10:18am
Bungee got excited too soon this morning with his Level II 2 hours before the start of the trading day. Low: 0.25$ within 15 minutes! Put, put, put ... _________________________________ Bunge - (2/16/2021 7:40:11 AM) L2 Level 2 Quote Hide Level 2 Quote Level two quotes - Bid Number of Shares  ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250